Search - tctmd.com

Displaying 241 - 260 of 433

Sort: Relevancy | Date

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

RIBS V Published: Good Outcomes with DEB, EES for BMS In-stent Restenosis Patients

January 22, 2014

News Daily News

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

January 22, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Yael L. Maxwell

January 09, 2014

News Daily News

Second-Generation DES the Better Choice for STEMI Patients

December 09, 2013

News Daily News

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

December 08, 2013

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

News Industry News

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

October 31, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

News Conference News TCT 2013

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

October 30, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Presenter: David Antoniucci

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Presenter: Young-Hak Kim

October 28, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

News Industry News

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

October 17, 2013

News Daily News

Paclitaxel-Eluting Balloon-Plus-BMS Strategy Fares Poorly vs. EES in De Novo Stenosis

October 15, 2013

Advertisement

Stent Malapposition Frequent, But Without Clinical Consequences

RIBS V Published: Good Outcomes with DEB, EES for BMS In-stent Restenosis Patients

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Second-Generation DES the Better Choice for STEMI Patients

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

ABSORB III and IV Trials Aim to Prove Superiority of BVS

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

Paclitaxel-Eluting Balloon-Plus-BMS Strategy Fares Poorly vs. EES in De Novo Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content